Forest Reclaiming Celexa Ahead Of Warner-Lambert Merger
Executive Summary
Forest is exercising its option to regain full marketing rights to the antidepressant Celexa (citalopram) under the change-in-control provisions of its co-promotion agreement with Warner-Lambert.
You may also be interested in...
Lipitor Holds Up In Merger Dispute; Warner-Lambert, Pfizer Beat Expectations
Warner-Lambert's Lipitor is showing no signs of a negative impact from the distractions caused by the hostile takeover bid launched by Warner's marketing partner Pfizer.
Lipitor Holds Up In Merger Dispute; Warner-Lambert, Pfizer Beat Expectations
Warner-Lambert's Lipitor is showing no signs of a negative impact from the distractions caused by the hostile takeover bid launched by Warner's marketing partner Pfizer.
Pfizer Lipitor Profitability Among Items In Dispute In Warner-Lambert Bid
The effect of the Lipitor co-promotion on Pfizer's earnings ranges from break-even to one quarter of profits, depending on which partner in the agreement is doing the accounting.